

Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma

James Miles, Christopher J. Applebee, Pierre Leboucher, Sonia Lopez-Fernandez, Dae-Jin Lee, Rosa Guarch, Stephen Ward, Peter J. Parker, Jose I. López, Banafshé Larijani

PII: S2214-6474(17)30036-3
DOI: doi:10.1016/j.bbacli.2017.10.002
Reference: BBACLI 161

To appear in:

Received date: 10 August 2017
Revised date: 11 October 2017
Accepted date: 11 October 2017

Please cite this article as: James Miles, Christopher J. Applebee, Pierre Leboucher, Sonia Lopez-Fernandez, Dae-Jin Lee, Rosa Guarch, Stephen Ward, Peter J. Parker, Jose I. López, Banafshé Larijani , Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bbacli(2017), doi:10.1016/j.bbacli.2017.10.002

Time Resolved Amplified FRET Identifies Protein Kinase B Activation State as a Marker for Poor Prognosis in Clear Cell Renal Cell Carcinoma

James Miles[1,5,7], Christopher J. Applebee[1], Pierre Leboucher[2], Sonia Lopez-Fernandez[1], Dae-Jin Lee[3], Rosa Guarch[4], Stephen Ward[5], Peter J. Parker[6], Jose I. López*[7] and Banafshé Larijani*[1]

[1]Cell Biophysics Laboratory, Ikerbasque, Basque Foundation for Science, FASTBASE SOLUTIONS Ltd, Research Centre for Experimental Marine Biology and Biotechnology (PiE) & Biofísika Institute (UPV/EHU, CSIC), University of the Basque Country, Spain
[2]Institut du Cerveau et de la Moelle épinière, Hôpital de la Pitié-Salpêtrière, Paris, France
[3]Basque Centre for Applied Mathematics, Bilbao, Bizkaia, Spain
[4]Department of Pathology B, Complejo Hospitalario de Navarra, Pamplona, Spain
[5]Department of Pharmacy and Pharmacology, University of Bath, UK
[6]Protein Phosphorylation Laboratory, The Francis Crick Institute, London, UK and Division of Cancer Studies, King's College London, London, UK.
[7]Department of Pathology, Cruces University Hospital, Biocruces Research Institute, University of the Basque Country (UPV/EHU), Barakaldo, Spain.

*Corresponding Authors:
Prof. Jose I. López (joseignacio.lopezfernandezdevillaverde@osakidetza.eus)
Prof. Banafshé Larijani (banafshe.larijani@ikerbasque.org)